VARUBI Rx

Select the drug indication to add to your list

VARUBI

Nausea
Only 4 drugs may be compared at once

Generic Name and Formulations:

Rolapitant 90mg; tabs.

Company:

Tesaro, Inc.

Select therapeutic use:

Indications for VARUBI:

In combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

Adult:

Give Varubi before starting each cycle, but at no less than 2 week intervals. ≥18yrs: Highly emetogenic cisplatin-based chemotherapy: 180mg approximately 1–2 hours prior to chemotherapy with dexamethasone 20mg PO/IV given 30 minutes prior to chemotherapy on Day 1, then dexamethasone 8mg PO/IV twice daily on Days 2–4 and a 5-HT3 receptor ­antagonist (see drug's full labeling for appropriate dosing) on Day 1. Moderately emetogenic chemotherapy and combinations of anthracycline and cyclophosphamide: 180mg approximately 1–2 hours prior to chemotherapy with dexamethasone 20mg PO/IV given 30 minutes prior to chemotherapy on Day 1 and a 5-HT3 receptor antagonist (see drug's full labeling for appropriate dosing) on Days 1– 4 (Note: NCCN guidelines do not require a 5-HT3 antagonist on Days 2–3).

Children:

<18yrs: not established.

Contraindications:

Concomitant thioridazine.

Warnings/Precautions:

Avoid in severe hepatic impairment; monitor if use cannot be avoided. Pregnancy. Nursing mothers.

Interactions:

See Contraindications. Increased risk of QT prolongation with concomitant pimozide; avoid. Avoid concomitant CYP2D6 or BCRP substrates with narrow therapeutic index (eg, dextromethorphan, methotrexate, topotecan, irinotecan); monitor if use cannot be avoided. Use lowest effective dose of rosuvastatin (see drug's full labeling for dosing). May potentiate digoxin, other P-gp substrates with narrow therapeutic index; monitor if use cannot be avoided. Antagonized by strong CYP3A4 inducers (eg, rifampin); avoid.

Pharmacological Class:

Substance P/NK1 receptor antagonist.

Adverse Reactions:

Neutropenia, hiccups, abdominal pain, decreased appetite, dizziness, dyspepsia, UTI, stomatitis, anemia.

Generic Availability:

NO

How Supplied:

Single dose pack—1 (2 x 90mg tab blisters)

VARUBI 90mg tablets (Qty:2)

appx. price $553.00